Oxford BioDynamics PLC OBD to present at China BIO Conference
May 08 2019 - 2:00AM
RNS Non-Regulatory
TIDMOBD
Oxford BioDynamics PLC
08 May 2019
8 May 2019
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the
"Group")
Oxford BioDynamics to present at China BIO Conference
Oxford BioDynamics Plc, a biotechnology company focused on the
discovery and development of epigenetic biomarkers based on
regulatory genome architecture, for use within the pharmaceutical
and biotechnology industry, today announces that it has been
selected to present at the China BIO Partnering Forum in Shanghai
on 8 May 2019 with a talk by the Company's Chief Scientific
Officer, Dr Alexandre Akoulitchev, entitled "EpiSwitch(TM)
Biomarkers: Practical Applications For Predictive, Prognostic And
Diagnostic Patient Stratifications".
The presentation will focus on validated EpiSwitch(TM) biomarker
applications which have demonstrated high efficacy in predictive,
prognostic and diagnostic patient stratifications for lung,
haematological, prostate, thyroid and skin cancers. Baseline
predictive stratifications by EpiSwitch(TM) for response to
immune-checkpoint inhibitors are excellent surrogates for standard
primary endpoints used in clinical trials, such as progression free
survival. The company has recently entered into its fifth
collaboration agreement for the development of predictive
biomarkers for immuno-oncology therapeutics with leading
pharmaceutical companies.
Alexandre Akoulitchev, Chief Scientific Officer, Oxford
BioDynamics said:
"We are looking forward to establishing new partnerships for
OBD's EpiSwitch(TM) technology in China. Our experience includes
working with American and European biopharmaceutical partners to
enable precision medicine initiatives through the incorporation of
our proprietary, epigenetic-based biomarker platform across the
research and development value chain. Recent milestones include the
co-development of a response biomarker to checkpoint inhibitor
therapy in non-small cell lung cancer (NSCLC), a disease subtyping
biomarker in diffuse B-cell lymphoma (DLBCL), a response biomarker
to first line therapy in rheumatoid arthritis (RA), a disease
progression biomarker in amyotrophic lateral sclerosis (ALS), and
diagnostic and prognostic biomarkers for non-alcoholic
steatohepatitis (NASH). Our partnering models are typically
structured as milestone-driven, collaborative R&D and licensing
deals and have already attracted significant interest from Chinese
Biotech."
-ENDS-
For further details please contact:
Oxford BioDynamics Plc
Christian Hoyer Millar,
CEO
Paul Stockdale, CFO +44 (0)1865 518910
FTI Consulting
Financial Public Relations
Adviser
Brett Pollard
Natalie Garland-Collins +44 (0)20 3727 1000
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a
biotechnology company focused on the discovery and development of
epigenetic biomarkers for use within the pharmaceutical and
biotechnology industry.
The Company's award-winning, proprietary technology platform,
EpiSwitch(TM), aims to accelerate the drug discovery and
development process, improve the success rate of therapeutic
product development and take advantage of the increasing importance
of personalised medicine.
In particular, EpiSwitch(TM) can reduce time to market, failure
rates and the costs at every stage of drug discovery. Additionally,
the technology provides significant insights into disease
mechanisms for drug discovery and product re--positioning
programmes, and enables the personalisation of therapeutics for
patients in the context of challenging pricing environments where
improved clinical outcomes are critical.
In April 2019, Oxford BioDynamics received the Queen's Award for
Enterprise: Innovation. The Queen's Awards for Enterprise are the
most prestigious awards for UK businesses.
The Company is headquartered in the UK and listed on the London
Stock Exchange's AIM under the ticker "OBD". For more information
please visit www.oxfordbiodynamics.com.
About China BIO 2019
ChinaBio(R) Partnering Forum is the premier life science
partnering event in China. The conference will be held May 8-9 in
Shanghai, attracting biotech and pharma leaders from around the
world along with hundreds of China-based developers of novel
technologies for two days of productive partnering.
The organizers expect over 1,400 delegates from more than 500
companies and 25 countries to attend, making it the largest
partnering conference in China.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRABDGDUUBGBGCR
(END) Dow Jones Newswires
May 08, 2019 02:00 ET (06:00 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From May 2023 to May 2024